- Home
- FBRX vs NYXH Comparison
FBRX vs NYXH Comparison
Compare FBRX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- NYXH
- Stock Information
- Founded
- FBRX N/A
- NYXH 2009
- Country
- FBRX United States
- NYXH Belgium
- Employees
- FBRX N/A
- NYXH N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- FBRX Health Care
- NYXH Health Care
- Exchange
- FBRX Nasdaq
- NYXH Nasdaq
- Market Cap
- FBRX 170.0M
- NYXH 188.1M
- IPO Year
- FBRX N/A
- NYXH 2021
- Fundamental
- Price
- FBRX $18.56
- NYXH $4.47
- Analyst Decision
- FBRX Strong Buy
- NYXH Strong Buy
- Analyst Count
- FBRX 3
- NYXH 3
- Target Price
- FBRX $68.00
- NYXH $12.67
- AVG Volume (30 Days)
- FBRX 108.4K
- NYXH 38.6K
- Earning Date
- FBRX 11-14-2025
- NYXH 11-13-2025
- Dividend Yield
- FBRX N/A
- NYXH N/A
- EPS Growth
- FBRX N/A
- NYXH N/A
- EPS
- FBRX N/A
- NYXH N/A
- Revenue
- FBRX N/A
- NYXH $6,616,215.00
- Revenue This Year
- FBRX N/A
- NYXH $85.62
- Revenue Next Year
- FBRX N/A
- NYXH $320.09
- P/E Ratio
- FBRX N/A
- NYXH N/A
- Revenue Growth
- FBRX N/A
- NYXH 10.96
- 52 Week Low
- FBRX $4.90
- NYXH $4.35
- 52 Week High
- FBRX $28.68
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- FBRX 66.60
- NYXH 37.54
- Support Level
- FBRX $18.11
- NYXH $4.41
- Resistance Level
- FBRX $21.99
- NYXH $4.75
- Average True Range (ATR)
- FBRX 1.78
- NYXH 0.28
- MACD
- FBRX 0.70
- NYXH -0.07
- Stochastic Oscillator
- FBRX 73.74
- NYXH 9.93
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.